Recursion said it earned its latest milestone payout by identifying differentiated, oral small molecule leads against a target the company described as a high interest immune cell target in immunology ...

The genome incorporation mechanism for LINE-1, the only autonomously active retrotransposon in humans, leverages the cell ...

Zevaskyn won FDA approval upon Abeona’s second filing of a biologics license application (BLA) for the therapy.

A first-in-human clinical trial tests a CRISPR/Cas9 gene-editing technique to help the immune system fight advanced gastrointestinal (GI) cancers.